Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study

NCT05922358 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT05922358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05922358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2023
Completion date
September 1, 2026
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal tumors